Home Newsfeeds Goldman Sachs Upgrades BioXcel Therapeutics to Neutral, Announces $16 Price Target

Goldman Sachs Upgrades BioXcel Therapeutics to Neutral, Announces $16 Price Target

Goldman Sachs analyst Corinne Jenkins upgrades BioXcel Therapeutics (NASDAQ:BTAI) from Sell to Neutral and announces $16 price target.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Goldman Sachs analyst Corinne Jenkins upgrades BioXcel Therapeutics (NASDAQ:BTAI) from Sell to Neutral and announces $16 price target.

Analyst Ratings

Where Douglas Emmett Stands With Analysts

By Benzinga Insights

October 18, 4:04 PM

Analysts have provided the following ratings for Douglas Emmett (NYSE:DEI) within the last quarter:

DEI

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

By Vandana Singh

December 22, 11:12 AM

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato

SNTI

Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

March 15, 1:20 PM

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.

$APE